Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : TAVA Technologies (TAVA-NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Brew who wrote (28552)	2/20/1999 6:15:00 PM
From: Bill Wexler	Respond to of 31646

<<Rejection and fraud are not the same thing>> Zonagen is fraudulently promoting a drug that doesn't work. This is not in dispute. Their own clinical trials and years of research on the effects of phentolamine demonstrate this fact beyond any reasonable doubt. Since the drug does not work, the drug will be rejected. I had similar arguments about a drug that TXB was promoting...Novastan. TXB is another Woddlands, Texas Biotech fraud financed by the same people who are involved in Zonagen. I correctly predicted the drug would be rejected and made a fortune shorting the stock. you may also want to take a look at the long term chart of ARNX...yet another biotech fraud with ties to Martin P. Sutter. You are seriously underestimating the time and research I put in many of my picks. I can't post "links" to much of the information I've accumulated because a lot of it simply isn't on the web. Much of it I had to struggle or pay for (e.g. private investigators, etc.) <<The only scam out here is you.>> Uh huh.